Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Chemed Corporation (NYSE:CHE - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 2,186 shares of the company's stock, valued at approximately $1,018,000.
Other hedge funds have also added to or reduced their stakes in the company. Monetary Solutions Ltd bought a new position in shares of Chemed during the 4th quarter valued at approximately $25,000. Los Angeles Capital Management LLC bought a new stake in shares of Chemed in the 4th quarter worth approximately $26,000. BOK Financial Private Wealth Inc. bought a new stake in shares of Chemed in the 4th quarter worth approximately $27,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in Chemed in the second quarter valued at approximately $34,000. Finally, Versant Capital Management Inc lifted its stake in Chemed by 7,500.0% in the second quarter. Versant Capital Management Inc now owns 76 shares of the company's stock valued at $35,000 after purchasing an additional 75 shares during the last quarter. Institutional investors own 95.85% of the company's stock.
Chemed Stock Up 0.0%
CHE stock opened at $523.57 on Monday. The company's 50 day moving average is $509.45 and its 200 day moving average is $449.68. The stock has a market cap of $6.84 billion, a price-to-earnings ratio of 26.30, a price-to-earnings-growth ratio of 1.98 and a beta of 0.51. The company has a current ratio of 0.91, a quick ratio of 0.89 and a debt-to-equity ratio of 0.17. Chemed Corporation has a 1-year low of $365.20 and a 1-year high of $557.00.
Chemed (NYSE:CHE - Get Free Report) last announced its quarterly earnings data on Tuesday, July 28th. The company reported $6.06 earnings per share for the quarter, topping analysts' consensus estimates of $5.60 by $0.46. Chemed had a net margin of 10.60% and a return on equity of 31.77%. The firm had revenue of $673.25 million during the quarter, compared to analyst estimates of $665.04 million. During the same period in the previous year, the business posted $4.27 EPS. The business's quarterly revenue was up 8.8% on a year-over-year basis. Chemed has set its FY 2026 guidance at 25.000-25.750 EPS. Sell-side analysts predict that Chemed Corporation will post 23.18 EPS for the current fiscal year.
Chemed Increases Dividend
The business also recently announced a quarterly dividend, which will be paid on Thursday, September 3rd. Stockholders of record on Monday, August 17th will be paid a dividend of $0.70 per share. This represents a $2.80 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend is Monday, August 17th. This is a positive change from Chemed's previous quarterly dividend of $0.60. Chemed's payout ratio is presently 14.06%.
Analysts Set New Price Targets
A number of equities research analysts recently issued reports on CHE shares. Weiss Ratings upgraded Chemed from a "hold (c-)" rating to a "hold (c)" rating in a research note on Friday, July 17th. Wall Street Zen upgraded shares of Chemed from a "hold" rating to a "strong-buy" rating in a research report on Saturday, August 1st. Bank of America reiterated a "neutral" rating on shares of Chemed in a research note on Wednesday, July 29th. Oppenheimer boosted their price target on shares of Chemed from $500.00 to $590.00 and gave the company an "outperform" rating in a research report on Friday, July 31st. Finally, Royal Bank Of Canada upped their price target on shares of Chemed from $436.00 to $548.00 and gave the company a "sector perform" rating in a research note on Thursday, July 30th. One investment analyst has rated the stock with a Buy rating and five have given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $530.75.
Get Our Latest Stock Report on CHE
Insider Activity at Chemed
In other news, CEO Kevin J. Mcnamara sold 2,000 shares of the stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $539.51, for a total value of $1,079,020.00. Following the completion of the transaction, the chief executive officer owned 70,418 shares of the company's stock, valued at approximately $37,991,215.18. This represents a 2.76% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Andrea R. Lindell sold 1,347 shares of the stock in a transaction that occurred on Tuesday, June 9th. The stock was sold at an average price of $447.33, for a total value of $602,553.51. Following the completion of the transaction, the director directly owned 4,578 shares of the company's stock, valued at $2,047,876.74. This represents a 22.73% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 6,537 shares of company stock worth $3,406,014 over the last ninety days. Corporate insiders own 3.33% of the company's stock.
About Chemed
(
Free Report)
Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.
The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.
Recommended Stories
Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Corporation (NYSE:CHE - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Chemed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemed wasn't on the list.
While Chemed currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
